ClinicalTrials.gg
RecruitingNCT05142189LuCa-MERIT-1Updated Jul 22, 2026

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

A Phase 1 interventional study of BNT116 and Cemiplimab in Non-Small Cell Lung Cancer, sponsored by BioNTech SE. Recruiting at 45 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by BioNTech SE · Phase 1, Interventional, and Treatment

How we know · 20 judgments

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
320
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Carcinoma, Non-Small-Cell Lung by BioNTech SE — 7 open to participants now, 8 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · BioNTech SE.

Planned enrollment
5th of 12
320 · median 231
Started
2022
the only one that year
Phase 1
5 of 12
1 open now
Registered
6th of 12
by date

Among the 12 studies in Carcinoma, Non-Small-Cell Lung by BioNTech SE, this one is the 5th largest by planned enrollment, is the only one that started in 2022, is one of 5 in phase 1, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 12 studies in Carcinoma, Non-Small-Cell Lung by BioNTech SE are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Carcinoma, Non-Small-Cell Lung by BioNTech SE, or all of them as a file.
02

Study summary

This first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicinal products (IMPs) including, but not limited to, cemiplimab, docetaxel, carboplatin, paclitaxel, osimertinib, anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), rearranged during transfection (RET) TKIs, BNT316 (an anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA-4] antibody), an anti-B7-H3 antibody conjugated to a topoisomerase I inhibitor, an anti-human epidermal growth factor receptor 3 (HER3) antibody conjugated to a topoisomerase I inhibitor or a bispecific antibody for programmed death ligand 1 (PD-L1) and vascular endothelial growth factor A (VEGF-A) in participants with non-small cell lung cancer (NSCLC).

The study will comprise several cohorts for dose confirmation in monotherapy as well as in combinations of BNT116 as mentioned above.

The study will enroll participants with NSCLC in advanced or metastatic stage in Cohorts 1 to 4 and Cohorts 7 to 10, unresectable NSCLC Stage III in Cohorts 5 and 11, resectable NSCLC of Stage II and III in Cohort 6, advanced/metastatic epidermal growth factor receptor (EGFR)-mutant NSCLC in Cohort EGFR, and advanced/metastatic ALK rearranged or RET rearranged NSCLC in Cohort ALK/RET.

Cohort EGFR and Cohort ALK/RET will enroll only at selected sites in the US.

Read the detailed description

The maximum duration of treatment for each individual participant in this study is:

  • Cohorts 1 to 4, Cohorts 7 to 10, Cohort EGFR, and Cohort ALK/RET: 24 months.
  • Cohorts 5 and 11: 18 cycles, i.e., 12 months.
  • Cohort 6: 4 cycles of neo-adjuvant treatment and 18 cycles of adjuvant treatment, i.e., 12 months of adjuvant treatment.
03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Cancer Vaccine
  • Non-Small Cell Lung Cancer
  • Combination with chemotherapy
  • Combination with other investigational agents
  • anti-B7-H3 antibody conjugated to topoisomerase I inhibitor
  • anti-HER3 antibody conjugated to topoisomerase I inhibitor
  • Immunotherapy
  • Antibody-drug conjugate (ADC)
  • Anaplastic lymphoma kinase (ALK) rearranged Non-Small Cell Lung Cancer
  • Rearranged during transfection (RET) rearranged Non-Small Cell Lung Cancer
  • NSCLC
  • anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody
  • Epidermal growth factor receptor (EGFR)-mutant Non-Small Cell Lung Cancer
  • Combination with a programmed cell death protein 1 (PD-1) inhibitor
  • Human epidermal growth factor receptor 3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants must have confirmed NSCLC and by v1.1. Note: Participants in Cohorts 1, 5 and 11 as well as in Cohorts EGFR and ALK/RET do not have to present with measurable disease.

    1. Participants must present with unresectable Stage III or Stage IV NSCLC by American Joint Commission on Cancer (AJCC) Cancer Staging Manual, Eighth Edition.

      EXCEPT

    2. Participants in Cohorts 5 and 11 must present with unresectable Stage III NSCLC by AJCC Cancer Staging Manual, Eighth Edition before receiving pre-study chemoradiotherapy.
    3. Participants in Cohort 6 with the initial diagnosis of resectable Stage II and Stage III NSCLC by AJCC Cancer Staging Manual, Eighth Edition.
  • Participants in Cohorts 2, 4, 5, 6, 10 and 11 must be able to tolerate (additional) therapy (i.e., did not permanently discontinue anti-programmed death protein 1 [PD-1] / PD-L1] therapy due to toxicity).
  • Participants must have an performance status (ECOG-PS) less than or equal to (\<=) 1, except for participants in Cohorts 1, 4, 5, 10 and 11 who are eligible with an ECOG-PS of 0-2.

Cohort-specific inclusion criteria:

Cohort 1:

  • Participants' prior therapy must have included at least a PD-1/PD-L1 inhibitor and a platinum-based chemotherapy regimen as well as one other (except if a participant is not candidate for a platinum-based chemotherapy and/or PD-1/PD-L1 inhibitor and/or another line of systemic therapy). Note: Participants newly enrolled in Cohort 1B under protocol v 5.0 and subsequent versions of the protocol must consent to mandatory blood sampling for peripheral blood mononuclear cells (PBMCs).
  • Participants who are to start cemiplimab at Cycle 3 must present with PD-L1 expression of tumor proportion score (TPS) greater than or equal to (>=) 1% in tumor cells (as determined locally).

Cohort 2:

  • Participants must present with PD-L1 expression of TPS >= 50% in tumor cells (as determined locally prior to inclusion in this study).
  • Participants must present with progressive disease either

    1. in the advanced or metastasized stage of NSCLC: while on a PD-1/PD-L1 inhibitor therapy or within 6 months of termination of this treatment as first-line treatment. Or
    2. be to ongoing therapy/maintenance treatment after CRT with a PD-1/PD-L1 inhibitor that has been given for at least 3 months in monotherapy (i.e., after an initial combination therapy) before being enrolled into this study.

Cohort 3:

  • Participants' prior therapy must have included at least a PD-1/PD-L1 inhibitor and a platinum-based chemotherapy regimen (except if a participant is not candidate for a platinum-based chemotherapy and/or PD-1/PD-L1 inhibitor).
  • Participants must present with progressive disease.

Cohort 4:

  • Participants who are not candidates for chemotherapy as first-line treatment for the advanced or metastasized stage of NSCLC may be enrolled if presenting with PD-L1 expression: TPS >= 1% in tumor cells (as determined locally).

Cohort 5:

  • Participants' NSCLC must have been considered unresectable due to participant's condition and/or tumor-related factors and the participants must have undergone chemoradiotherapy before entering the study.

Cohort 6:

  • Participants' NSCLC must be considered technically and medically resectable.
  • Participants must be considered eligible for neo-adjuvant treatment.

Cohort 7:

  • Participants' prior therapy must have included at least a PD-1/PD-L1 inhibitor and a platinum-based chemotherapy regimen (except if a participant is not a candidate for a platinum-based chemotherapy and/or PD-1/PD-L1 inhibitor). Note 1: Participants may have received prior therapy targeting CTLA-4, lymphocyte-activation gene 3 (LAG-3), T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain (TIGIT), VEGF or VEGF receptor (VEGFR) inhibitor as monotherapy or part of a combination therapy. Note 2: If the participants' prior therapies included a CTLA-4 inhibitor, the participant must be able to tolerate (additional) treatment with the CTLA-4 inhibitor.
  • Participants must present with progressive disease at study enrollment.
  • Participants must consent to mandatory blood sampling for PBMCs.

Cohorts 8 \& 9:

  • Participants' prior therapy must have included at least a PD-1/PD-L1 inhibitor and a platinum-based chemotherapy regimen (except if a participant is not a candidate for a platinum-based chemotherapy and/or PD-1/PD-L1 inhibitor).
  • Participants must present with progressive disease at study enrollment.

Cohort 10:

  • Participants who are not candidates for chemotherapy as first-line treatment for the advanced or metastasized stage of NSCLC may be enrolled.

Cohort 11:

  • Participants' NSCLC must have been considered unresectable due to participants condition and/or tumor related factors and the participants must have undergone chemoradiotherapy before entering the study.

Cohort EGFR (will enroll only at selected sites in the US):

  • Participants' NSCLC must have classical EGFR mutations, i.e., ex19Del or L858R.
  • Participants must have ongoing treatment with osimertinib.

Cohort ALK/RET (will enroll only at selected sites in the US):

  • Participants' NSCLC must have ALK rearrangement or RET rearrangement.
  • Participants must have ongoing treatment with a standard of care ALK TKI or RET TKI.

Key Exclusion Criteria:

  • Ongoing active systemic treatment against NSCLC.
  • Presence of a driver mutation for which approved target therapies are available except if the participant is not a candidate for the respective targeted therapy. EXCEPT participants in Cohort EGFR and Cohort ALK/RET.
  • Ongoing or recent evidence (within the last 5 years) of significant disease that required treatment with systemic treatments which may suggest risk for immune-related adverse events. Note: Participants with autoimmune-related hyperthyroidism, autoimmune-related hypothyroidism who are in remission, or on a stable dose of thyroid-replacement hormone, vitiligo, or psoriasis may be included.
  • Current evidence of new or growing brain or spinal metastases during screening. Participants with are excluded. Participants with known brain or spinal metastases may be eligible for all Cohorts, except for Cohorts 5, 6 and 11, if they:
  • had radiotherapy or another appropriate therapy for the brain or spinal metastases, AND
  • have no neurological symptoms that can be attributed to the current brain lesions, AND
  • have stable brain or spinal disease on the computed tomography (CT) or magnetic resonance imaging (MRI) scan within 4 weeks before signing the (confirmed by stable lesions on two scans at least 4 weeks apart), AND
  • do not require therapy for the treatment of brain or spinal metastases within 14 days before the first dose of study treatment. Note: Spinal bone metastases (that is, of the vertebrae) are allowed, unless imminent fracture or cord compression is anticipated.
  • Systemic immune suppression:
  • Current use of chronic systemic steroid medication (\<= 5 mg/day prednisolone equivalent is allowed); participants using physiological replacement doses of prednisone for adrenal or pituitary insufficiency are eligible. Note: Steroid medication given for supportive or prophylactic reasons during CRT for participants in Cohorts 5 and 11 needs to be tapered to \<= 5 mg/day prednisolone equivalent at latest on the day before the study treatment starts.
  • Other systemic immune suppression within the last 3 months before study enrollment.
  • Known history of seropositivity for (HIV) with cluster of differentiation 4 (CD4)+ T-cell (CD4+) counts less than (\<) 350 cells/microlitre (mcL) and with a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections.
  • Prior splenectomy.
  • History/risk of interstitial lung disease or low baseline lung function (baseline pulse oximetry of less than 92% oxygen saturation without additional oxygen).

NOTE: Other protocol defined Inclusion/Exclusion criteria apply to all or some participants depending on the cohort.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    Cohort 1A - BNT116 Monotherapy

    Biological: BNT116

  • Experimental
    Cohort 1B - BNT116 Monotherapy

    Biological: BNT116

  • Experimental
    Cohort 2 - BNT116 + Cemiplimab (PD-1/PD-L1 Inhibitor Refractory/Relapsed Participants)

    Biological: BNT116 · Biological: Cemiplimab

  • Experimental
    Cohort 3 - BNT116 + Docetaxel

    Biological: BNT116 · Drug: Docetaxel

  • Experimental
    Cohort 4 - BNT116 + Cemiplimab (Frail Participants)

    Biological: BNT116 · Biological: Cemiplimab

  • Experimental
    Cohort 5 - BNT116 + Cemiplimab (After Concurrent Chemoradiotherapy [CRT])

    Biological: BNT116 · Biological: Cemiplimab

  • Experimental
    Cohort 6 - BNT116 + Cemiplimab + Carboplatin + Paclitaxel

    BNT116 + cemiplimab + carboplatin + paclitaxel as neo-adjuvant treatment followed by surgery, thereafter adjuvant treatment with BNT116 + cemiplimab

    Biological: BNT116 · Biological: Cemiplimab · Drug: Carboplatin · Drug: Paclitaxel

  • Experimental
    Cohort 7 - BNT116 + BNT316

    Dose finding for the combination of BNT116 with BNT316 (CTLA4 antibody) with dose escalation of BNT316

    Biological: BNT116 · Biological: BNT316

  • Experimental
    Cohort 8: BNT116 + Anti-B7-H3 Antibody Conjugated to Topoisomerase I Inhibitor

    Dose finding for the combination of BNT116 with an anti-B7-H3 antibody conjugated to a topoisomerase I inhibitor with dose escalation of the anti-B7-H3 antibody conjugated to a topoisomerase I inhibitor

    Biological: BNT116 · Biological: anti-B7-H3 antibody conjugated to topoisomerase I inhibitor

  • Experimental
    Cohort 9: BNT116 + Anti-HER3 Antibody Conjugated to Topoisomerase I Inhibitor

    Dose confirmation for the combination of BNT116 with an anti-HER3 antibody conjugated to a topoisomerase I inhibitor with dose escalation of the anti-HER3 antibody conjugated to a topoisomerase I inhibitor

    Biological: BNT116 · Biological: anti-HER3 antibody conjugated to topoisomerase I inhibitor

  • Experimental
    Cohort 10: BNT116 + Bispecific Antibody for PD-L1 and VEGF-A (Frail Participants)

    Dose confirmation for BNT116 in combination with a bispecific antibody for programmed death ligand 1 (PD-L1) and vascular endothelial growth factor A (VEGF-A) will be established.

    Biological: BNT116 · Biological: Bispecific antibody for PD-L1 and VEGF-A

  • Experimental
    Cohort 11: BNT116 + Bispecific Antibody for PD-L1 and VEGF-A (After Concurrent CRT)

    Dose confirmation for BNT116 in combination with a bispecific antibody for PD-L1 and VEGF-A will be established in participants after concurrent CRT.

    Biological: BNT116 · Biological: Bispecific antibody for PD-L1 and VEGF-A

  • Experimental
    Cohort EGFR : BNT116 + osimertinib

    Dose confirmation for BNT116 in combination with ongoing osimertinib therapy. Treatment with osimertinib is standard of care. Cohort will enroll only at selected sites in the US.

    Biological: BNT116 · Biological: Osimertinib

  • Experimental
    Cohort ALK/RET: BNT116 + ALK TKI or RET TKI

    Dose confirmation for BNT116 in combination with either ongoing ALK-inhibitor or ongoing RET-inhibitor therapy. Treatment with ALK TKI or RET TKI is standard of care. Cohort will enroll only at selected sites in the US.

    Biological: BNT116 · Biological: ALK-inhibitor or RET-inhibitor

Interventions

  • BiologicalBNT116

    Intravenous injection

  • BiologicalCemiplimab

    Intravenous infusion

  • Intravenous infusion

  • Intravenous infusion

  • Intravenous infusion

  • BiologicalGotistobartStudies of GotistobartGotistobart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous infusion

  • Biologicalanti-B7-H3 antibody conjugated to topoisomerase I inhibitor

    Intravenous infusion

  • Biologicalanti-HER3 antibody conjugated to topoisomerase I inhibitor

    Intravenous infusion

  • BiologicalBispecific antibody for PD-L1 and VEGF-A

    Intravenous infusion

  • BiologicalOsimertinib

    Oral

  • BiologicalALK-inhibitor or RET-inhibitor

    Oral

06

What researchers measure

Primary outcomes

  1. Cohorts 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, EGFR and ALK/RET: Occurrence of Dose-Limiting Toxicities (DLTs) During the DLT Observation Period

    Cohort EGFR and Cohort ALK/RET will enroll only at selected sites in the US.

    Time frame: From first dose of IMP up to 21 days

  2. Cohorts 1 to 11, EGFR and ALK/RET: Occurrence of Treatment-Emergent Adverse Events (TEAEs) Reported by Relationship, Seriousness, and Grade

    According to National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0). Cohort EGFR and Cohort ALK/RET will enroll only at selected sites in the US.

    Time frame: up to 27 months

  3. Cohort 6 only: Occurrence of Post-Surgical Adverse Events (AEs) Related to BNT116 and Cemiplimab

    Time frame: up to 27 months

  4. Cohort 6 only: Occurrence of Treatment-Related Delays to Surgery More Than 9 weeks Post the Last Dose of Neo-Adjuvant Treatment

    Time frame: up to 6 months

Secondary outcomes

  1. Cohorts 1, 2, 3, 4, 7, 8, 9, and 10: Overall Response Rate (ORR)

    ORR defined as the number of participants with complete response (CR) or partial response (PR) as best overall response (BOR) according to response evaluation criteria in solid tumors (RECIST) v1.1 divided by the number of participants in the efficacy analysis set.

    Time frame: up to 27 months

  2. Cohorts 1, 2, 3, 4, 7, 8, 9, and 10: Duration of Response (DoR)

    DoR defined as the time from initial response until first objective tumor progression according to RECIST v1.1.

    Time frame: up to 27 months

  3. Cohorts 1, 2, 3, 4, 7, 8, 9, and 10: Disease Control Rate (DCR)

    DCR defined as the number of participants with CR or PR or stable disease (SD) as BOR according to RECIST v1.1 divided by the number of participants in the efficacy analysis set.

    Time frame: up to 27 months

  4. Cohorts 1, 2, 3, 4, 7, 8, 9, and 10: Duration of Disease Control

    Duration of disease control defined as the time from initial detection of stable disease or response until first objective tumor progression according to RECIST v1.1.

    Time frame: up to 27 months

  5. Cohorts 1, 2, 3, 4, 7, 8, 9, and 10: Progression-Free Survival (PFS)

    PFS defined as the time of first study treatment until the first objective tumor progression according to RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: up to 48 months

  6. Cohorts EGFR (osimertinib): PFS

    Defined as the time of first treatment with osimertinib until the first objective tumor progression according to RECIST v1.1 or death from any cause, whichever occurs first. Cohort EGFR will enroll only at selected sites in the US.

    Time frame: up to 48 months

  7. Cohort ALK/RET (ALK TKI or RET TKI): PFS

    Defined as the time of first treatment with a ALK TKI or RET TKI until the first objective tumor progression according to RECIST v1.1 or death from any cause, whichever occurs first. Cohort ALK/RET will enroll only at selected sites in the US.

    Time frame: up to 48 months

  8. Cohorts EGFR and ALK/RET: (BNT116): PFS per molecular NSCLC subtype

    Defined as the time of first treatment with BNT116 until the first objective tumor progression according to RECIST v1.1 or death from any cause, whichever occurs first. Cohort EGFR and Cohort ALK/RET will enroll only at selected sites in the US.

    Time frame: up to 48 months

  9. Cohorts 1-11: Overall Survival (OS)

    OS defined as the time of first study treatment until death from any cause.

    Time frame: up to 48 months

  10. Cohorts 5, 6 and 11: Event Free Survival (EFS)

    EFS defined as the length of time from first study treatment to any of the following events: progression of disease, recurrence of disease or death from any cause, whichever occurs first.

    Time frame: up to 48 months

  11. Cohort 6: Rate of Pathologic Responses

    Rate of pathologic responses defined as the number of participants with major or complete pathologic response in the surgical specimen from surgery after neo-adjuvant study treatment divided by the number of participants in the efficacy analysis set.

    Time frame: At time of surgery (approximately after 3 months treatment)

  12. Cohorts 5, 6 and 11: EFS Rate at 12 and 24 months

    EFS rate defined as the number of participants without an EFS-defining event divided by the number of participants in the efficacy analysis set.

    Time frame: up to 24 months

  13. Cohort 6: ORR at the End of Neo-Adjuvant Treatment (Using RECIST v1.1)

    ORR defined as the number of participants with CR or PR as BOR according to RECIST v1.1 divided by the number of participants in the efficacy analysis set.

    Time frame: up to 3 months

  14. Cohort 6: Rate of Progressive Disease at the End of Neo-Adjuvant Treatment (Using RECIST v1.1)

    Time frame: up to 3 months

07

Study locations

41 of 45 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Feb 2030, 92 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 92 months is above that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2021
First posted
Dec 2, 2021
StartActual
Jun 17, 2022
Primary completionEst.
Feb 2030
CompletionEst.
Nov 2031
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05142189
Lead sponsor
BioNTech SE
Responsible party
Sponsor
First posted
Dec 2, 2021
Start date
Jun 17, 2022
Primary completion
Feb 2030 (estimated)
Completion
Nov 2031 (estimated)
Last update
Jul 22, 2026

Study contacts

BioNTech clinical trials patient information
Contact
patients@biontech.de
+49 6131 9084 ext. 0
BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion